A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Splitting the difference on promising pipeline asset predictions
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Two haemophilia A subjects help Sangamo erase 2019's losses
Promising early data with Sangamo and Pfizer’s haemophilia A gene therapy could set up a battle with Roche and Biomarin.
Upcoming events – Pfizer and Glycomimetics await sickle cell data and Biocryst tries again
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
Should gene therapy patients be asked to pay?
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
How to pay for gene therapies in developing nations
With rich countries like the US finding it hard to fund gene therapies, it is worth asking whether these projects will ever reach patients in developing countries. And if…
Vertex and Crispr up the ante in gene therapy chase
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.